| Expression pattern: |
DN |
| Associated gene: |
PURB, ADGRB1, MDM2, p53, AGO2 |
| Associated microRNA: |
miR-3191-5p |
| Biological function: |
Suppresses ICC cell proliferation, migration, invasion, tumor growth and liver metastasis; acts as a tumor suppressor. |
| Molecular mechanism: |
Acts as a transcriptional co-activator with PURB to enhance ADGRB1 transcription and as a miRNA sponge for miR-3191-5p to upregulate ADGRB1; ADGRB1 inhibits MDM2-mediated p53 polyubiquitination to activate p53 signaling. |
| Biological pathway or process: |
p53 signaling (promotes); proliferation (inhibits); migration (inhibits); invasion (inhibits); metastasis (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
circRNA-seq; RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; Agarose Gel Electrophoresis; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RNA Pull-Down; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; ChIP / ChIP-seq; Transfection; CCK8; EdU Staining; Colony Formation Assay; Transwell Assay; Wound Healing Assay; Western Blot; Co-IP; IHC (Immunohistochemistry); In Vivo Animal Model; H&E Staining; IF (Immunofluorescence); Bioinformatics Analysis; Clinical Sample Validation; Cohort Study; Survival Analysis |
| Clinical significance: |
Reduced circUGP2 levels are associated with unfavorable prognosis and advanced TNM stage in ICC patients. |
| Description: |
circUGP2 is down-regulated in intrahepatic cholangiocarcinoma and acts as a tumor suppressor. It binds PURB to co-activate ADGRB1 transcription and sponges miR-3191-5p to further increase ADGRB1, which blocks MDM2-mediated p53 polyubiquitination and activates p53 signaling, thereby inhibiting ICC growth and metastasis. |
| Confidence score: |
0.9034 |